Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study | Zendy

Mark Sulkowski | Zendy; Minhee Kang | Zendy; Roy M. Matining | Zendy; David Wyles | Zendy; Victoria A. Johnson | Zendy; Gene D. Morse | Zendy; Valerianna Amorosa | Zendy; Debika Bhattacharya | Zendy; Kristine Coughlin | Zendy; Flossie WongStaal | Zendy; Marshall J. Glesby | Zendy

Open Access

Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study

Author(s) -

Mark Sulkowski,

Minhee Kang,

Roy M. Matining,

David Wyles,

Victoria A. Johnson,

Gene D. Morse,

Valerianna Amorosa,

Debika Bhattacharya,

Kristine Coughlin,

Flossie WongStaal,

Marshall J. Glesby

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit503

Subject(s) - medicine , placebo , hepatitis c virus , adverse effect , hepacivirus , hepatitis c , cohort , randomized controlled trial , gastroenterology , confidence interval , immunology , virus , pathology , alternative medicine

Hepatitis C virus (HCV) entry involves scavenger receptor B1 (SRB1). In vitro, SRB1 inhibition by ITX5061 impedes HCV replication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore